Steeve Neron, Chief Commercial Officer of Tetra, said, “Tetra will need several trusted sources of APIs, such as Avicanna’s, to support QIXLEEF™ operations leading to its successful marketing clearance. QIXLEEF™ is Tetra’s proprietary investigational new drug and is currently being evaluated in two US FDA-cleared clinical trials. Additionally, Avicanna’s established distribution channels in Latin America and South America can help advance the commercialization of Tetra’s products in certain jurisdictions.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) is a leader in the discovery and development of cannabinoid-derived drugs with an FDA and Health Canada approved clinical program aimed at delivering new prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has allowed them to develop a pipeline of cannabinoid drug products for a range of medical conditions, including pain, inflammation and oncology. With patients at the heart of its business, Tetra Bio-Pharma is focused on providing the rigorous scientific validation and safety data needed for inclusion in the existing biopharmaceutical industry by regulators, physicians and insurance companies. .

For more information visit: www.tetrabiopharma.com

About Avicanna Inc.

Avicanna is an innovative, commercial and international biopharmaceutical company focused on the development, advancement and commercialization of evidence-based cannabinoid products for the global consumer, as well as the medical and pharmaceutical market segments. Leading global cannabinoid advancements, Avicanna conducts its research in Canada at its R&D headquarters at the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The Society actively collaborates with major Canadian academic and medical institutions. Avicanna has established a cutting-edge scientific platform including advanced R&D and clinical development that has led to the commercialization of over thirty products in four main market segments:

  • Medical cannabis and wellness products : Marketed under the RHO Phyto™ brand, these medical and wellness products are an advanced line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a comprehensive list of products including oral, sublingual, topical and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by preclinical data. The advanced form is marketed with education and training for consumers, patients and the medical community.
  • CBD Dermo-Cosmetic Products : Marketed under the Pura H&W™ or Pura Earth™ brand names, these registered and clinically tested dermo-cosmetic products include a portfolio of functional CBD topical products.
  • Pharmaceutical pipeline : Leveraging Avicanna’s scientific platform, vertical integration and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and at various stages of development clinic and marketing. These cannabinoid-based drug candidates provide solutions to unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is in the drug registration phase in South America.
  • Cannabinoid raw materials: Marketed under the Aureus™ brand, the company’s raw materials business has successfully achieved sales in 12 countries. Aureus™ offers dried cannabis flowers, standardized seeds, full-spectrum extracts and cannabinoid distillates, isolated cannabinoids such as CBD, THC, cannabigerol (“CBG”) and other rare cannabinoids. Aureus™ products are manufactured in Santa Marta Golden Hemp SAS, the company’s majority-owned subsidiary in Colombia, which is also GACP certified and has the United States Department of Agriculture’s USDA National Organic Program certification for its hemp cultivars.

SOURCEAvicanna Inc.

Stay logged in

For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at [email protected] or follow us on social media at LinkedIn, Twitter, Facebook or Instagram.

The Company posts updates via videos on the Company’s official YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.

Caution Regarding Forward-Looking Information and Statements

This press release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information in this press release can be identified by the use of words such as “may”, “could”, “might”, “will”, “likely”, “expect”, “anticipate”. , ‘believe’, ‘intent’, ‘plan’, ‘forecast’, ‘project’, ‘estimate’, ‘outlook’ and other similar expressions . Forward-looking information in this press release includes, but is not limited to, statements relating to anticipated financial and/or operating results and prospects, including anticipated revenues, anticipated sales growth, anticipated expansion of product listings, anticipated application of its products by the Company, anticipated growth, anticipated geographic expansion, receipt of regulatory clearances and approvals , the success of clinical trials, scientific advances and developments, the successful commercialization of products, the Company’s priorities, objectives and strategies, industry trends and their anticipated impact, the anticipated impact of current market conditions on each of our segments and near-term expectations, supply chain components and constraints, and Company financial statement estimates and assumptions. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on forward-looking information as the Company cannot guarantee that it will prove to be accurate. Actual results and developments may differ materially from those contemplated by such statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. These risks and uncertainties include, but are not limited to, current and future market conditions, including the trading price of the Company’s common shares, and the risk factors set forth in the Company’s Annual Information Form dated September 3, 2021. and the abbreviated final prospectus dated November 27, 2020, filed with the Canadian securities authorities and available under the Company’s profile on SEDAR at www.sedar.com. The statements contained in this press release are made as of the date of this press release. The Company disclaims any intention or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Forward-looking financial information

The financial outlook and forward-looking financial information contained in this press release regarding financial performance, financial condition or prospective earnings are based on assumptions about future events, including economic conditions and proposed courses of action, the basis of management’s evaluation of the relevant information currently available. In particular, this presentation contains information on the Company’s 2022 financial outlook, including expected revenues. These projections contain forward-looking information and are based on a number of important assumptions and factors set forth above and are provided to give the reader a better understanding of the Company’s potential future performance in certain areas. Actual results may differ materially from the projections presented here. These projections may also be considered to contain forward-looking financial information or financial outlook. The actual results of the Company’s operations for any period will likely vary from the amounts shown in these projections, and such variations may be material. See above as well as the “Risk Factors” set forth in the Company’s Annual Information Form dated September 3, 2021 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the profile of the Company on SEDAR at www. sedar.com for a more in-depth discussion of the risks that could cause actual results to vary. Readers are cautioned that the financial outlook and forward-looking financial information contained herein should not be used for any purpose other than that for which it is disclosed herein.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dec8f178-991b-406e-9d56-37e29fef9ff2

main logo

Michael P. Boser